Recent progress in antiretrovirals - lessons from resistance

被引:35
作者
Adamson, Catherine S. [1 ]
Freed, Eric O. [1 ]
机构
[1] NCI, Virus Cell Interact Sect, HIV Drug Resistance Program, Frederick, MD 21702 USA
关键词
D O I
10.1016/j.drudis.2008.02.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent failures in efforts to develop an effective vaccine against HIV-1 infection have emphasized the importance of antiretroviral therapy in treating HIV-1-infected patients. Thus far, inhibitors of two viral enzymes, reverse transcriptase and protease, have had a profoundly positive impact on the survival of HIV-1-infected patients. However, new inhibitors that act at diverse steps in the viral replication cycle are urgently needed because of the development of resistance to currently available antiretrovirals. This review summarizes recent progress in antiretroviral drug discovery and development by specifically focusing on novel inhibitors of three phases of replication: viral entry, integration of the viral DNA into the host cell genome and virus particle maturation.
引用
收藏
页码:424 / 432
页数:9
相关论文
共 94 条
[61]   The causes and consequences of HIV evolution [J].
Rambaut, A ;
Posada, D ;
Crandall, KA ;
Holmes, EC .
NATURE REVIEWS GENETICS, 2004, 5 (01) :52-61
[62]   Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics [J].
Reeves, JD ;
Gallo, SA ;
Ahmad, N ;
Miamidian, JL ;
Harvey, PE ;
Sharron, M ;
Pöhlmann, S ;
Sfakianos, JN ;
Derdeyn, CA ;
Blumenthal, R ;
Hunter, E ;
Doms, RW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (25) :16249-16254
[63]   The HIV coreceptor switch: a population dynamical perspective [J].
Regoes, RR ;
Bonhoeffer, S .
TRENDS IN MICROBIOLOGY, 2005, 13 (06) :269-277
[64]   Antiviral drug resistance [J].
Richman, Douglas D. .
ANTIVIRAL RESEARCH, 2006, 71 (2-3) :117-121
[65]   Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptide [J].
Rimsky, LT ;
Shugars, DC ;
Matthews, TJ .
JOURNAL OF VIROLOGY, 1998, 72 (02) :986-993
[66]   USFDA approves new class of HIV therapeutics [J].
Robertson, D .
NATURE BIOTECHNOLOGY, 2003, 21 (05) :470-471
[67]  
Rusconi S, 2007, CURR TOP MED CHEM, V7, P1273
[68]   Keynote review:: Progress in targeting HIV-1 entry [J].
Ryser, HJP ;
Flückiger, R .
DRUG DISCOVERY TODAY, 2005, 10 (16) :1085-1094
[69]   3-O-(3′,3′-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro [J].
Sakalian, M ;
McMurtrey, CP ;
Deeg, FJ ;
Maloy, CW ;
Li, F ;
Wild, CT ;
Salzwedel, K .
JOURNAL OF VIROLOGY, 2006, 80 (12) :5716-5722
[70]  
Salzwedel K, 2007, AIDS REV, V9, P162